Johnson & Johnson: Investment Opportunities and Growth Potential

Investor Favorite: Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is one of the stocks closely examined by Jim Cramer recently. Cramer stated that if investors own these stocks, they would "perform very well." He said, "If you want to go beyond the 'consumer packaged goods' (CPG) world, owning J&J or Amgen stocks would be a good choice."

J&J is exiting areas it does not operate in within its business model and is focusing on the high-growth potential pharmaceutical sector. The company specializes particularly in cancer treatments and also offers a return of over 2.7%. Cramer said, "I want to avoid thinking too strongly about how I feel regarding old safe stocks; therefore, I suggested that at least one should be added to our investment club portfolio."

Johnson & Johnson is a company that develops and sells health products. The company's portfolio includes treatments in areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases. It also offers surgical systems, orthopedic solutions, cardiovascular devices, and vision health products.

Although JNJ has investment potential, it is worth mentioning that certain artificial intelligence (AI) stocks offer higher profit potential and carry less risk. If you are looking for a very undervalued AI stock that will significantly benefit from Trump-era tariffs and the local production trend, we recommend reviewing our free report on the best short-term AI stocks.